PIPELINE – 2012
Utilizing our AIMSelectTM, AIMProveTM platforms and our HIS-mouse model AIMM Therapeutics is establishing a pipeline of novel antibodies to treat diseases with high unmet medical need and for which a clear clinical development path has been established. Current focus: cancer, infectious, auto-immune and inflammatory diseases. Early programs that targeted infectious diseases have produced best-in-class and first-in-class antibodies that are currently in late stage IND enabling studies. More recent programs in oncology, inflammation, and auto immune diseases have produced antibodies with impressive affinities to tumor selective and ‘self antigens’ that discriminate against normal background tissue.